Myovant shares soar 27% on news of Pfizer prostate cancer drug collaboration worth up to $4.2 billion – MarketWatch
Shares of Myovant Sciences soared 27% Monday, after its parent Sumitovant Biopharma unveiled an agreement with Pfizer Inc. to jointly develop a treatment for prostate cancer and women’s health in a deal worth up to $4.2 billion in upfront and potential milestone payments.
will receive an upfront payment of $650 million to develop and market relugolix, a once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist, which won approval from the U.S. Food and Drug Administration in December as a treatment for advanced prostate cancer.
If approved, the two companies will also develop and market relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) targeting women’s health in the U.S. and Canada. They will start co-promoting the treatment, which will be sold as Orgovyx, as a prostate cancer treatment in early 2021.
The companies will equally share profits and certain costs, while Myovant will record revenue. Myovant will also be responsible for interactions with the regulator and for drug supply and clinical development. The company will be entitled to $200 million in potential regulatory milestones for FDA approvals for relugolix combination tablet in women’s health, and to tiered sales milestones upon reaching up to $2.5 billion in net sales for prostate cancer and women’s health indications.
“There continues to be a high unmet need among the millions of women who experience the common and debilitating symptoms associated with uterine fibroids and endometriosis,” said Nick Lagunowich, global president, Pfizer Internal Medicine PFE,
Evercore analyst Josh Schimmer said the deal is positive for Myovant.
“After having some time to digest it, we like it,” Schimmer wrote in a note to clients. “While It gives up half the economics of relugolix (which we hadn’t modelled), that’s adequately offset by adding PFE’s commercial efforts as well as the billions of milestones which we think are achievable.”
Myovant is one of five companies under the Sumitovant umbrella.
Prostate cancer is one of the most comment among men, apart from skin cancer, according to Cancer.net. An estimated 191,930 men will be diagnosed with the illness this year, about 60% of whom will be over 65.
Myovant shares have gained 84% in 2020, while the SPDR S&P Biotech ETF XBI,
has gained 57% and the S&P 500 SPX,
has gained 16%.
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.